ovariectomy

Cimicifugoside H1 shows the protective function to cerebral neuron during cerebral ischemia.

E0924G is an orally active PPARδ agonist with an EC50 of 2.82 μM. It enhances the upregulation of osteoprotegerin (OPG) expression, with an EC50 of 0.29 μM. E0924G reduces RANKL-induced osteoclast differentiation and inhibits F-actin ring formation in RAW264.7 macrophages. Additionally, E0924G modulates bone density and bone loss in models of ovariectomy (OVX) and age-related osteoporosis.

Anti-osteoporosis agent-12 (Compound 18) is an orally active pyrazole-fused betulinic acid derivative that exhibits strong anti-osteoporotic properties. It powerfully inhibits RANKL-induced osteoclastogenesis in RAW264.7 cells, with an IC50 of 7.96 nM. Additionally, Anti-osteoporosis agent-12 dose-dependently improves key micro-CT parameters of bone, reduces serum bone resorption marker levels (CTx), and effectively prevents bone loss induced by ovariectomy. This agent is useful for osteoporosis research.

E8431 is a DCSTAMP antagonist, where DCSTAMP is a crucial fusion protein that coordinates cell-cell fusion during osteoclastogenesis. E8431 inhibits cytoskeletal reorganization mediated by the RAP1B-RAC1 signaling pathway. It has the ability to prevent pre-osteoclast fusion, suppress bone resorption, and stimulate PDGFBB secretion, thereby promoting bone and vessel formation. E8431 effectively reduces bone loss in mouse models induced by ovariectomy. This compound can be used for osteoporosis research.

ABD-295 is an antiresorptive agent, osteoclast inhibitor, and biphenylsulfide derivative. ABD-295 has potent inhibitory effects on osteoclastic bone resorption in vitro. ABD-295 prevents ovariectomy-induced bone loss in vivo.

Puerarin 6''-O-xyloside possesses significant anti-osteoporotic activity on ovariectomy mice, it has significant antitumour activities, the mechanisms are related to increased levels of caspase-3, caspase-7, caspase-9 and Bax, and reduced levels Bcl-2.

iso-Dehydrozingerone is a novel osteoclastogenesis inhibitor, preventing ovariectomy-induced osteoporosis in ddY mice.

1. β-Anhydroicaritin exhibits immunosuppressive effect on the mouse macrophages stimulated by LPS. 2. β-Anhydroicaritin phytosomes can inhibit enhanced bone turnover induced by ovariectomy, improve BMD the biomechanical properties of vertebrae, without any stimulation on uterus. 3. β-Anhydroicaritin possesses significant protective effects on the zymosan-induced peritonitis mice, which might be associated with the regulation of Ca(2+); influx in macrophages and iNOS expression.

VnP-16, a synthetic peptide fragment mirroring amino acids 270-281 of vitronectin (a multifunctional glycoprotein involved in cell attachment, migration, and spreading), promotes attachment and spreading of isolated human osteogenic cells. This effect is reversible with β1 integrin siRNA knockdown when VnP-16 is applied at 9.1 µg/cm2 on cell plates. The compound enhances osteogenesis in human skin-derived mesenchymal precursors and MC3T3-E1 mouse calvarial osteoblast precursors. Furthermore, in vivo studies show VnP-16 mitigates IL-1α-induced bone loss, reduces calvarial osteoclast numbers in mice, increases bone mineral density, and lessens trabecular bone loss in a mouse model of ovariectomy-induced bone loss.

Puerarin 6''-O-Xyloside (Standard) is a reference standard for research and analysis in studies involving Puerarin 6''-O-Xyloside. Puerarin 6''-O-xyloside possesses significant anti-osteoporotic activity on ovariectomy mice, it has significant antitumour activities, the mechanisms are related to increased levels of caspase-3, caspase-7, caspase-9 and Bax, and reduced levels Bcl-2.